MRC Technology Completes Move to Stevenage Open Innovation Campus
News Apr 20, 2016
MRC Technology, an independent life science medical research charity, has completed the move of its Centre for Therapeutics Discovery to state-of-the-art laboratory facilities at the Stevenage Bioscience Catalyst (SBC) campus. Some teams will also relocate from the central London office. The charity will still have an office in London, along with laboratories and an office in Edinburgh.
The move marks the next stage in MRC Technology’s mission to be a catalyst for life changing science, improving human health and advancing medical research. Through the open innovation network of the SBC campus, MRC Technology will have access to increased opportunities to collaborate with industry, charities, universities and health organisations to speed up life science discovery and translation processes.
Dave Tapolczay, Chief Executive Officer, MRC Technology, commented: “This is an exciting phase in MRC Technology’s development. The move provides the increased laboratory space and facilities needed to drive research and development programmes, so we can help more organisations progress innovative medical science and find solutions to some pressing health issues.”
From its inception in 2000, MRC Technology projects have led to 12 drugs on the market including Tysabri®, Actemra®, Entyvio® and Keytruda®. Research partnerships have been formed with over 40 universities and academic institutes, and alliances with 20 medical research charities. MRC Technology has generated over £630M in royalty income for research partners, enabling them to fund additional research.
MIT researchers have developed a cryptographic system that could help neural networks identify promising drug candidates in massive pharmacological datasets, while keeping the data private. Secure computation done at such a massive scale could enable broad pooling of sensitive pharmacological data for predictive drug discovery.
Biochemists, microbiologists, drug discovery experts and infectious disease doctors have teamed up in a new study that shows antibiotics are not always necessary to cure sepsis in mice. Instead of killing causative bacteria with antibiotics, researchers treated infected mice with molecules that block toxin formation in bacteria.READ MORE